Blocking the PD‐L1/PD1 axis has been shown to be an effective therapy for targeting tumors with an inflamed tumor microenvironment, including melanoma, bladder cancer, gastric cancer, and non‐small cell lung cancer.[23] However, PDAC is generally considered a non‐immunogenic tumor with limited infiltration of activated T cells. Here, CD274 is linked to melanoma.